App-Quantinova.ai

Anticoagulation Treatment with Low Molecular-Weight Heparin for Portal Vein Thrombosis in Liver Cirrhosis: Efficacy and Risk of Hemorrhagic Complications

Youngil Koh - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Venous thrombosis

dalteparin Subcutaneous

Incidence and Risk Factors for Venous Thromboembolism in Patients with Spinal Cord Injury: A Retrospective Study

Siavash Piran - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Interm Report of the Highlow Study: A Randomized Controlled Trial Comparing Two Doses of Low Molecular Weight Heparin for the Prevention of Pregnancy-Associated Recurrent Venous Thromboembolism

Suzanne M Bleker - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Major Bleeding Events Among Cancer and Non-Cancer Patients Taking Rivaroxaban for Venous Thromboembolism Treatment in a Department of Defense Health System Cohort

Alok A. Khorana - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

rivaroxaban

Safety of Doacs in Patients of Extreme Weight

Laura Talamo - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy

Qian Jiang - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

L-Tyrosine

Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN

Ambra Di Veroli - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma

Sruthi Adimadhyam - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Christine G Kohn - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

Quality and Value-Focused Decision Making in Heparin-Induced Thrombocytopenia: The Impact of the American Society of Hematolog-s Choosing Wisely Initiative

Anmol Baranwal - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Trends in Hospital Cost, Length of Stay, Mortality, and Complication Rates in Patients with Acute Myeloid Leukemia in Teaching Versus Non-Teaching Hospitals: Data from the Nationwide Inpatient Sample from 1999-2013

Ankit Shah - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Acute Myeloid Leukemia in the Elderly: Trends in Mortality Rates, Hospital Cost, Length of Stay, and Complication Rates in Patients Aged 60 and Older

Ankit Shah - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Postoperative Venous Thromboembolism in Children Is Increased in Setting of Cancer or Infection

Harold J. Leraas - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

The Pregnancy Course and Outcomes during Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria

Maria A. Vinogradova - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Venous thrombosis

Eculizumab

Incidence and Risk Factors for Venous Thrombosis in Human Immunodeficiency Virus (HIV) Infection, Data from the Dutch Athena Cohort Study

James Francis Borjas-Howard - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

the Long-Term Recurrence Risk of Patients with Unprovoked Venous Thromboembolism: An Observational Cohort Study

Paul A Kyrle - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Elevated Levels of Circulating Nucleosomes Are Not Associated with Venous Thrombosis or Neutrophil Activation in Patients with Multiple Myeloma

Mandy N. Lauw - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Interleukin

Increased Levels of Endothelial Dysfunction Markers and Matrix Metalloproteinases in Patients with Severe Post-Thrombotic Syndrome

Luis Fernando Bittar - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Thrombomodulin alfa

Real-Life Incidence of Cancer Following a First Unprovoked Venous Thrombosis: Results from the Epigetbo Study

Aurelien Delluc - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Hospital Associated Venous Thromboembolism in Oklahoma County

Natalie Feland - American Society of Hematology (ASH) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Filters

7277 Abstracts